Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30314386 | 1.00 | GAA (0.41) | GAACRBNDDB1EPHX2HTR2C | |
| SCHEMBL29014262 | 1.00 | GAA (0.41) | GAACRBNDDB1EPHX2HTR2C | |
| SCHEMBL25875348 | 0.87 | GAA (0.43) | GAACRBNDDB1EPHX2RIPK1 | |
| SCHEMBL23887515 | 0.85 | CRBN (0.42) | CRBNDDB1HTR2CMTNR1AMTNR1B | |
| SCHEMBL23887518 | 0.85 | CRBN (0.42) | CRBNDDB1HTR2CMTNR1AMTNR1B | |
| SCHEMBL23555100 | 0.81 | EPHX2 (0.46) | GAACRBNDDB1EPHX2RIPK1 | |
| SCHEMBL30160156 | 0.81 | EPHX2 (0.46) | GAACRBNDDB1EPHX2RIPK1 | |
| SCHEMBL30314212 | 0.78 | RIPK1 (0.56) | RIPK1BACE1 | |
| SCHEMBL23900326 | 0.78 | RIPK1 (0.56) | RIPK1BACE1 | |
| SCHEMBL29014325 | 0.78 | RIPK1 (0.56) | RIPK1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-115867548-A | RIP1K inhibitors | 里格尔药品股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11584758-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584758-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4126864-A1 | RIP1K INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20210317135-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2021203011-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584758-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | GAA 1283/4885CRBN 2484/4885DDB1 511/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | GAA 1283/4885CRBN 2484/4885DDB1 511/4885 |
| US-20210317135-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | GAA 1283/4885CRBN 2484/4885DDB1 511/4885 |
| US-20230227469-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | GAA 1283/4885CRBN 2484/4885DDB1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.